Posted by Michael Wonder on 31 Aug 2016
Accelerating global innovation to address antibacterial resistance: introducing CARB-X
30 August 2016 - A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance.
The latest issue of Nature Reviews Drug Discovery introduces CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
